Mountain Valley MD Holdings Inc. announced that it has successfully formulated its Ivectosol™ product and provided trial quantities to its Bio Safety Level 4 ("BSL-4") laboratory partner. The trials are immediately commencing as scheduled. As previously outlined, the study is designed to prove the superiority of the Company's solubilized Ivermectin technology versus commercially available oral form in speed and efficacy of COVID-19 viral clearance and will also include the more virulent B.1.351 South African COVID-19 variant. Inactivated Polio Vaccine – Dose Sparing Adjuvant: Additionally, the dose sparing adjuvant formulation work for the Inactivated Polio Vaccine has been completed by MVMD and Tulane University School of Medicine has confirmed it will be commencing its trials the week of March 8, 2021.